In research trying to understand my PSMA-negative FDG-positive current scenario I've come across some interesting articles that I thought I'd share with the group. I'm consulting with a new MO on Wednesday and I'm hoping she can shed some light on my progression.
This paper came out 2 weeks ago- it's a long read, but provides info on the five distinctive histologic and expression-based subtypes of mCRPC : adenocarcinoma (AR+/NE−), double-positive (AR+/NE+), low AR (ARL/NE−), neuroendocrine (AR−/NE+), and double-negative (AR−/NE−)
aacrjournals.org/cancerres/...
This U of M article talks about the role of ARSi utilization and how it leads to mCRPC in a more laymans approach.